

# Efstathios Kastritis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1528920/publications.pdf>

Version: 2024-02-01

652  
papers

28,122  
citations

13332

70  
h-index

8433

152  
g-index

658  
all docs

658  
docs citations

658  
times ranked

27636  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
2	BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. <i>Cell</i> , 2011, 146, 904-917.	13.5	2,432
3	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
4	Hematological findings and complications of COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 834-847.	2.0	1,354
5	Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors. <i>Journal of Clinical Oncology</i> , 2005, 23, 8580-8587.	0.8	990
6	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	0.8	735
7	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. <i>Blood</i> , 2013, 121, 3420-3427.	0.6	385
8	Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 20, 493-506.	1.9	351
9	Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. <i>Annals of Oncology</i> , 2009, 20, 117-120.	0.6	347
10	Diagnosis of monoclonal gammopathy of renal significance. <i>Kidney International</i> , 2015, 87, 698-711.	2.6	339
11	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	4.1	330
12	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	0.8	294
13	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410.	13.9	291
14	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	1.7	289
15	Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1031-1037.	0.8	273
16	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
17	Pathogenesis and treatment of renal failure in multiple myeloma. <i>Leukemia</i> , 2008, 22, 1485-1493.	3.3	259
18	How I treat monoclonal gammopathy of renal significance (MGRS). <i>Blood</i> , 2013, 122, 3583-3590.	0.6	259

#	ARTICLE	IF	CITATIONS
19	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.	3.3	259
20	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.	1.9	232
21	Response assessment in Waldenström's macroglobulinaemia: update from the 13th International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176.	1.2	226
22	Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. <i>Haematologica</i> , 2006, 91, 968-71.	1.7	223
23	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 241-250.	5.1	212
24	Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 120-126.	0.8	207
25	Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , 2013, 122, 3276-3282.	0.6	180
26	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. <i>Haematologica</i> , 2007, 92, 1351-1358.	1.7	179
27	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). <i>Leukemia</i> , 2009, 23, 1152-1157.	3.3	176
28	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
29	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	0.6	161
30	Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. <i>Haematologica</i> , 2007, 92, 546-549.	1.7	160
31	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.	0.8	154
32	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy. <i>International Journal of Cancer</i> , 2012, 131, 1466-1471.	2.3	150
33	Daratumumab plus CyBORd for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <i>Blood</i> , 2020, 136, 71-80.	0.6	146
34	Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. <i>Leukemia</i> , 2013, 27, 947-953.	3.3	141
35	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5904-5909.	0.8	139
36	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.	0.6	138

#	ARTICLE	IF	CITATIONS
37	The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. <i>Leukemia</i> , 2013, 27, 423-429.	3.3	137
38	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.	3.3	137
39	Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , 2015, 125, 3085-3099.	0.6	136
40	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.	0.6	130
41	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021, 83, 1-16.	1.7	127
42	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. <i>Annals of Oncology</i> , 2014, 25, 195-200.	0.6	126
43	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	2.8	126
44	Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. <i>Leukemia</i> , 2010, 24, 1769-1778.	3.3	120
45	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020, 7, e112-e121.	2.2	119
46	The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. <i>Leukemia</i> , 2008, 22, 2247-2256.	3.3	117
47	The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. <i>Leukemia</i> , 2014, 28, 2402-2403.	3.3	115
48	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	1.7	112
49	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.	0.6	108
50	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. <i>Trends in Molecular Medicine</i> , 2022, 28, 542-554.	3.5	104
51	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	2.8	103
52	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	0.8	102
53	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 302-306.	1.4	101
54	Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. <i>Annals of Oncology</i> , 2012, 23, 2681-2686.	0.6	98

#	ARTICLE	IF	CITATIONS
55	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	2.2	96
56	Proteasome inhibitor associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2016, 91, E348-52.	2.0	95
57	Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 904-916.	1.2	91
58	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.	2.5	89
59	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. <i>Blood</i> , 2012, 119, 5384-5390.	0.6	88
60	Recent advances in the management of AL Amyloidosis. <i>British Journal of Haematology</i> , 2016, 172, 170-186.	1.2	88
61	Adjuvant Chemotherapy With Paclitaxel and Carboplatin in Patients With Advanced Carcinoma of the Upper Urinary Tract: A Study by the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 2150-2154.	0.8	87
62	Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor- $\kappa$ B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. <i>Acta Oncologica</i> , 2007, 46, 221-229.	0.8	83
63	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
64	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. <i>Blood</i> , 2019, 133, 710-723.	0.6	82
65	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. <i>American Journal of Hematology</i> , 2012, 87, 861-864.	2.0	81
66	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. <i>Radiology</i> , 2017, 282, 484-493.	3.6	81
67	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81
68	The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2006, 106, 297-303.	2.0	78
69	Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2021, 798, 149014.	3.9	76
70	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2008, 49, 890-895.	0.6	74
71	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.	2.0	73
72	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.	1.7	72

#	ARTICLE	IF	CITATIONS
73	Treatment of light chain deposition disease with bortezomib and dexamethasone. <i>Haematologica</i> , 2009, 94, 300-302.	1.7	70
74	Cardio-oncology: A Focus on Cardiotoxicity. <i>European Cardiology Review</i> , 2018, 13, 64.	0.7	65
75	How I treat Waldenström macroglobulinemia. <i>Blood</i> , 2019, 134, 2022-2035.	0.6	65
76	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	0.8	65
77	The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. <i>Annals of Oncology</i> , 2005, 16, 307-313.	0.6	64
78	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010, 34, 1395-1397.	0.4	64
79	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv41-iv50.	0.6	63
80	Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. <i>Leukemia</i> , 2010, 24, 1206-1212.	3.3	62
81	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017, 129, 456-459.	0.6	62
82	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62.	0.8	62
83	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	1.2	61
84	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. <i>Haematologica</i> , 2009, 94, 372-379.	1.7	60
85	Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. <i>Cancer</i> , 2005, 103, 2629-2635.	2.0	58
86	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.	1.2	58
87	Somatic mutations of adenomatous polyposis coli gene and nuclear β-catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication. <i>International Journal of Cancer</i> , 2009, 124, 103-108.	2.3	57
88	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2018-2023.	0.6	57
89	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014, 28, 2075-2079.	3.3	57
90	Validation of the International Prognostic Scoring System (IPSS) for Waldenström's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.	0.4	56

#	ARTICLE	IF	CITATIONS
91	Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015, 90, E60-5.	2.0	55
92	Increased expression of macrophage inflammatory protein-1 $\alpha$ on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. <i>Leukemia</i> , 2009, 23, 2177-2181.	3.3	54
93	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. <i>American Journal of Hematology</i> , 2014, 89, 803-808.	2.0	54
94	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	0.6	54
95	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 830-844.	2.5	54
96	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	3.3	53
97	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. <i>BMC Medicine</i> , 2021, 19, 208.	2.3	52
98	Treatment of Relapsed/Refractory Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 143-157.	1.8	49
99	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	2.0	48
100	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.	1.7	48
101	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. <i>European Journal of Cancer</i> , 2020, 126, 125-135.	1.3	48
102	The evolving role of lenalidomide in the treatment of hematologic malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 497-509.	0.9	46
103	Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment. <i>Oncology</i> , 2007, 73, 290-297.	0.9	46
104	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	46
105	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
106	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem cell transplantation: Results of a single institution, randomized phase 2 trial. <i>American Journal of Hematology</i> , 2010, 85, 863-867.	2.0	44
107	Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015, 100, e446-e449.	1.7	44
108	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	0.6	44

#	ARTICLE	IF	CITATIONS
109	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	1.7	44
110	The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. <i>Gynecologic Oncology</i> , 2005, 99, 376-382.	0.6	43
111	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011, 86, 479-483.	2.0	43
112	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015, 94, 2033-2042.	0.8	43
113	Treatment of plasma cell dyscrasias with lenalidomide. <i>Leukemia</i> , 2008, 22, 1343-1353.	3.3	42
114	The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. <i>Haematologica</i> , 2008, 93, 1420-1422.	1.7	42
115	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	3.4	42
116	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 1-7.	1.4	42
117	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8787-8803.	2.9	41
118	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e299-e309.	2.2	41
119	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013, 88, 765-770.	2.0	40
120	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	3.3	40
121	Increased Serum Lactate Dehydrogenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 409-413.	0.2	39
122	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.	2.8	39
123	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	2.5	39
124	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	1.8	38
125	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. <i>British Journal of Haematology</i> , 2007, 137, 560-568.	1.2	37
126	Novel approaches for reducing free light chains in patients with myeloma kidney. <i>Nature Reviews Nephrology</i> , 2012, 8, 234-243.	4.1	37



#	ARTICLE	IF	CITATIONS
127	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC. <i>European Journal of Haematology</i> , 2013, 91, n/a-n/a.	1.1	37
128	Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. <i>Blood</i> , 2016, 128, 405-409.	0.6	37
129	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	1.1	37
130	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	2.5	37
131	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	0.6	37
132	Clinicopathological features of ovarian carcinosarcomas: a single institution experience. <i>Gynecologic Oncology</i> , 2005, 96, 136-142.	0.6	35
133	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.	2.8	35
134	Immunogenic Cell Death, DAMPs and Prothymosin $\hat{\pm}$ as a Putative Anticancer Immune Response Biomarker. <i>Cells</i> , 2022, 11, 1415.	1.8	34
135	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 34-40.	2.0	33
136	Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. <i>Blood Cancer Journal</i> , 2017, 7, e571-e571.	2.8	33
137	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <i>Rheumatology International</i> , 2020, 40, 1353-1360.	1.5	33
138	Circulating angiopoietin $\hat{\epsilon}$ 1 to angiopoietin $\hat{\epsilon}$ 2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. <i>International Journal of Cancer</i> , 2012, 130, 735-742.	2.3	32
139	VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. <i>Leukemia</i> , 2014, 28, 928-934.	3.3	32
140	A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 35, 103-110.	0.4	31
141	Targeted therapies in multiple myeloma. <i>Targeted Oncology</i> , 2009, 4, 23-36.	1.7	31
142	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. <i>European Journal of Haematology</i> , 2014, 92, 308-312.	1.1	31
143	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. <i>Blood Cancer Journal</i> , 2017, 7, e570-e570.	2.8	31
144	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020, 10, 214.	1.1	31

#	ARTICLE	IF	CITATIONS
145	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	0.8	31
146	Sclerostin: a possible target for the management of cancer-induced bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 761-769.	1.5	30
147	Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. <i>Haematologica</i> , 2012, 97, 1699-1703.	1.7	30
148	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. <i>OncoTargets and Therapy</i> , 2013, 6, 531.	1.0	30
149	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	1.9	30
150	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.	2.8	29
151	A randomized phase 3 study of ixazomib+dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , 2022, 36, 225-235.	3.3	29
152	Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 50-52.	1.4	28
153	Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. <i>European Journal of Haematology</i> , 2010, 85, 1-5.	1.1	28
154	Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. <i>Leukemia and Lymphoma</i> , 2011, 52, 2299-2303.	0.6	28
155	The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. <i>Annals of Oncology</i> , 2012, 23, 722-729.	0.6	28
156	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. <i>European Journal of Haematology</i> , 2012, 89, 10-15.	1.1	28
157	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2165-2177.	0.9	28
158	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	1.9	28
159	Prognostic factors for multiple myeloma in the era of novel therapies. <i>Expert Review of Hematology</i> , 2018, 11, 863-879.	1.0	28
160	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. <i>HemaSphere</i> , 2020, 4, e454.	1.2	28
161	Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. <i>Haematologica</i> , 2009, 94, 725-728.	1.7	28
162	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. <i>Blood</i> , 2010, 116, 1574-1574.	0.6	28

#	ARTICLE	IF	CITATIONS
163	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	0.6	28
164	A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. <i>Annals of Oncology</i> , 2004, 15, 1250-1255.	0.6	27
165	Response to bortezomib of a patient with scleromyxedema refractory to other therapies. <i>Leukemia Research</i> , 2011, 35, e209-e211.	0.4	27
166	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1477-1495.	0.9	27
167	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.	0.6	27
168	Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment. <i>Urology</i> , 2005, 65, 126-130.	0.5	26
169	Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 994-999.	1.2	26
170	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. <i>Leukemia Research</i> , 2010, 34, 399-402.	0.4	26
171	Methyljasmonate displays <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 159, 340-351.	1.2	26
172	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.	1.5	26
173	Emerging antibodies for the treatment of multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 225-237.	1.0	25
174	Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. <i>Scientific Reports</i> , 2019, 9, 3245.	1.6	25
175	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	2.1	25
176	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2010, 116, 988-988.	0.6	25
177	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	1.1	25
178	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.	0.6	24
179	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	1.4	24
180	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.	1.7	24

#	ARTICLE	IF	CITATIONS
181	Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2006, 133, 301-304.	1.2	23
182	An overview of the role of carfilzomib in the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1883-1897.	0.9	23
183	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. <i>Blood Cancer Journal</i> , 2018, 8, 102.	2.8	23
184	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.2	23
185	Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract. <i>Journal of Clinical Oncology</i> , 2008, 26, 1555-1557.	0.8	22
186	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.	2.0	22
187	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 19-23.	1.4	22
188	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51.	0.8	22
189	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 3-17.	1.4	22
190	A review of the venous thrombotic issues associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 695-706.	1.0	21
191	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	2.0	21
192	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 109.	2.8	21
193	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	1.4	21
194	The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. <i>Anticancer Research</i> , 2006, 26, 3865-9.	0.5	21
195	The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2007, 104, 372-376.	0.6	20
196	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	0.2	20
197	Bortezomib for AL amyloidosis: moving forward. <i>Blood</i> , 2011, 118, 827-828.	0.6	20
198	Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients. <i>International Journal of Dentistry</i> , 2014, 2014, 1-7.	0.5	20

#	ARTICLE	IF	CITATIONS
199	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.	0.2	20
200	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	1.2	20
201	Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece. <i>Medicine (United States)</i> , 2020, 99, e23845.	0.4	20
202	Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study. <i>Blood</i> , 2018, 132, 149-149.	0.6	20
203	Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. <i>Cancer Management and Research</i> , 2013, 5, 37.	0.9	19
204	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1723-1726.	0.6	19
205	Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. <i>Blood Cancer Journal</i> , 2016, 6, e428-e428.	2.8	19
206	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. <i>Blood</i> , 2020, 136, 24-26.	0.6	19
207	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. <i>Blood</i> , 2010, 116, 1364-1364.	0.6	19
208	Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience. <i>Oncology</i> , 2006, 70, 265-272.	0.9	18
209	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11.	1.4	18
210	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	1.2	18
211	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 1935-1935.	0.6	18
212	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. <i>Radiology</i> , 2022, 304, 137-144.	3.6	18
213	Angiogenetic Factors and Biochemical Markers of Bone Metabolism in POEMS Syndrome Treated with High-Dose Therapy and Autologous Stem Cell Support. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 73-76.	1.4	17
214	Thalidomide in the treatment of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 681-699.	0.7	17
215	Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience. <i>Tumori</i> , 2011, 97, 25-29.	0.6	17
216	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2304-2309.	0.6	17

#	ARTICLE	IF	CITATIONS
217	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. <i>Scientific Reports</i> , 2017, 7, 17802.	1.6	17
218	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	2.5	17
219	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	1.2	17
220	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	0.8	17
221	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	1.2	17
222	Carboplatin Hypersensitivity Reactions: A Single Institution Experience. <i>Journal of Chemotherapy</i> , 2005, 17, 104-110.	0.7	16
223	Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. <i>Leukemia and Lymphoma</i> , 2007, 48, 754-758.	0.6	16
224	Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. <i>Oncology</i> , 2007, 72, 388-396.	0.9	16
225	Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 56-61.	0.2	16
226	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.	2.0	16
227	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 335-340.	0.2	16
228	High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e482-e482.	2.8	16
229	Neutrophil Gelatinase-Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 29-35.	0.2	16
230	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 25.	2.8	16
231	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2021, 26, 861-879.	1.7	16
232	How I treat relapsed multiple myeloma. <i>Blood</i> , 2022, 139, 2904-2917.	0.6	16
233	Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2006, 102, 124-127.	0.6	15
234	Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. <i>Blood Cancer Journal</i> , 2015, 5, e319-e319.	2.8	15

#	ARTICLE	IF	CITATIONS
235	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2006.	1.7	15
236	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	2.8	15
237	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021, 193, 113-118.	1.2	15
238	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.	3.3	15
239	Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. <i>Journal of Clinical Oncology</i> , 2021, 39, 8003-8003.	0.8	15
240	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	0.9	15
241	The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate. <i>Blood</i> , 2005, 106, 637-637.	0.6	15
242	Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. <i>Leukemia and Lymphoma</i> , 2004, 45, 2275-2279.	0.6	14
243	Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 773-779.	0.6	14
244	Managing renal complications in multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 839-850.	1.0	14
245	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, e381.	1.2	14
246	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021, 9, 546.	1.6	14
247	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. <i>Cells</i> , 2022, 11, 1241.	1.8	14
248	Schnitzler's Syndrome: Increased Levels of Bone Formation and Angiogenesis Factors Are Reduced After Successful Pefloxacin Treatment. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 359-362.	1.4	13
249	Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics. <i>Annals of Oncology</i> , 2016, 27, 233-240.	0.6	13
250	Emerging treatment approaches for myeloma-related bone disease. <i>Expert Review of Hematology</i> , 2017, 10, 217-228.	1.0	13
251	Evaluating ibrutinib in the treatment of symptomatic Waldenström's macroglobulinemia. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 291-300.	0.7	13
252	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 93.	2.8	13

#	ARTICLE	IF	CITATIONS
253	Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First-Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. <i>Blood</i> , 2020, 136, 26-26.	0.6	13
254	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.. <i>Blood</i> , 2005, 106, 363-363.	0.6	13
255	High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 425-425.	0.6	13
256	Macrophage Inflammatory Protein-1 alpha (MIP-1 $\alpha$ ) Is Increased in Patients with Waldenstrom's Macroglobulinemia and Correlates with the Severity of Disease.. <i>Blood</i> , 2005, 106, 2498-2498.	0.6	13
257	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.	1.8	13
258	Angiogenesis in Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 46-49.	1.4	12
259	Rituximab-Based Treatments in Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 59-61.	1.4	12
260	Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 197-205.	1.9	12
261	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Cancers</i> , 2020, 12, 2864.	1.7	12
262	Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5185.	1.8	12
263	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.	2.0	12
264	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.	2.1	12
265	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	1.7	12
266	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	0.6	12
267	Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,. <i>Blood</i> , 2011, 118, 3922-3922.	0.6	12
268	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. <i>Blood</i> , 2012, 120, 438-438.	0.6	12
269	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. <i>Blood</i> , 2015, 126, 4178-4178.	0.6	12
270	Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. <i>Anticancer Research</i> , 2007, 27, 611-7.	0.5	12



#	ARTICLE	IF	CITATIONS
271	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. <i>British Journal of Haematology</i> , 2010, 150, 587-591.	1.2	11
272	Prevention and Treatment of Myeloma Bone Disease. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 249-257.	1.2	11
273	Proteasome Inhibitors in Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 829-840.	0.9	11
274	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 163-171.	0.6	11
275	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	2.0	11
276	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	1.2	11
277	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 103-110.	1.4	11
278	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020, 136, 48-50.	0.6	11
279	Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ).. <i>Blood</i> , 2007, 110, 3519-3519.	0.6	11
280	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 35-35.	0.6	11
281	Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7501-7501.	0.8	11
282	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021, 106, 2940-2946.	1.7	11
283	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2022, 126, 79-90.	2.9	11
284	Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 115-117.	0.2	10
285	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.	0.6	10
286	How We Manage Patients with Plasmacytomas. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 227-235.	1.2	10
287	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	2.3	10
288	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 57-62.	0.2	10

#	ARTICLE	IF	CITATIONS
289	Solid Organ Transplantation in Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 352-364.	0.7	10
290	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.	0.2	10
291	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.	1.0	10
292	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. <i>Oncotarget</i> , 2018, 9, 17797-17809.	0.8	10
293	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	2.1	10
294	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. <i>Frontiers in Immunology</i> , 2021, 12, 746203.	2.2	10
295	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	2.5	10
296	Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.	2.0	10
297	An update on the use of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1865-1877.	0.9	9
298	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.	0.6	9
299	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	0.8	9
300	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	0.6	9
301	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	0.8	9
302	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471.	2.0	9
303	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e905-e909.	0.2	9
304	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021, 13, 1257.	1.7	9
305	How I treat elderly patients with plasma cell dyscrasias. <i>Aging</i> , 2018, 10, 4248-4268.	1.4	9
306	Hematological malignancies: myeloma. <i>Annals of Oncology</i> , 2006, 17, x136-x143.	0.6	8



#	ARTICLE	IF	CITATIONS
325	Cardiac amyloidosis: in search of the ideal diagnostic tool. <i>Herz</i> , 2021, 46, 9-14.	0.4	7
326	Exercise-Induced Changes in Tumor Growth via Tumor Immunity. <i>Sports</i> , 2021, 9, 46.	0.7	7
327	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. <i>HemaSphere</i> , 2021, 5, e614.	1.2	7
328	The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.. <i>Blood</i> , 2009, 114, 1729-1729.	0.6	7
329	Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. <i>Blood</i> , 2010, 116, 2963-2963.	0.6	7
330	Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. <i>Blood</i> , 2012, 120, 1819-1819.	0.6	7
331	Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8546-8546.	0.8	7
332	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. <i>Oncotarget</i> , 2018, 9, 36906-36913.	0.8	7
333	Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. <i>Clinical Nephrology</i> , 2016, 85 (2016), 44-54.	0.4	7
334	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 117-118.	2.0	7
335	Biomarkers in AL Amyloidosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10916.	1.8	7
336	Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 656-669.	1.0	7
337	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020, 136, 48-49.	0.6	7
338	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.	1.4	7
339	The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. <i>Insights Into Imaging</i> , 2022, 13, 55.	1.6	7
340	Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 690-691.	4.3	6
341	Proteasome Inhibitor Therapy for Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 235-237.	0.2	6
342	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. <i>European Journal of Haematology</i> , 2017, 99, 449-458.	1.1	6

#	ARTICLE	IF	CITATIONS
343	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017, 35, 734-740.	0.8	6
344	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.	0.6	6
345	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. <i>Blood</i> , 2008, 112, 869-869.	0.6	6
346	The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients.. <i>Blood</i> , 2009, 114, 1815-1815.	0.6	6
347	How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.	0.8	6
348	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.	1.7	6
349	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. <i>Blood</i> , 2021, 138, 153-153.	0.6	6
350	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. <i>Blood</i> , 2021, 138, 2730-2730.	0.6	6
351	Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2005, 26, 627-31.	0.3	6
352	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study âœœREBUILDâœœ. <i>Cancers</i> , 2022, 14, 2768.	1.7	6
353	Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8076-TPS8076.	0.8	6
354	The role of novel drugs in multiple myeloma. <i>Annals of Oncology</i> , 2008, 19, vii121-vii127.	0.6	5
355	Emerging drugs for WaldenstrÃ¶m's macroglobulinemia. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 45-57.	1.0	5
356	When a little aspirin may be enough. <i>Blood</i> , 2012, 119, 905-906.	0.6	5
357	Current therapy guidelines for Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 194-205.	0.7	5
358	Disease control should be the goal of therapy for WM patients. <i>Blood Advances</i> , 2017, 1, 2483-2485.	2.5	5
359	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrÃ¶m Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437.	0.2	5
360	The Spectrum of Ocular Manifestations in Patients with WaldenstrÃ¶m's Macroglobulinemia. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-10.	1.0	5

#	ARTICLE	IF	CITATIONS
361	Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. <i>Blood</i> , 2020, 136, 37-40.	0.6	5
362	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 44-45.	0.6	5
363	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 6-7.	0.6	5
364	Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.. <i>Blood</i> , 2007, 110, 1484-1484.	0.6	5
365	Bortezomib+Melphalan+Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.. <i>Blood</i> , 2008, 112, 1727-1727.	0.6	5
366	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. <i>Blood</i> , 2011, 118, 995-995.	0.6	5
367	Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient. <i>Blood</i> , 2013, 122, 3195-3195.	0.6	5
368	Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8011-8011.	0.8	5
369	Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group. <i>Blood</i> , 2011, 118, 5084-5084.	0.6	5
370	Liver and Gastrointestinal Involvement. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, e1-e13.	0.9	5
371	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110583.	1.1	5
372	Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. <i>American Journal of Hematology</i> , 2022, 97, E27.	2.0	5
373	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3886-3886.	0.6	5
374	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. <i>Blood</i> , 2021, 138, 2721-2721.	0.6	5
375	Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. <i>Blood</i> , 2021, 138, 159-159.	0.6	5
376	How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. <i>Leukemia and Lymphoma</i> , 2007, 48, 2295-2297.	0.6	4
377	Appraising myc involvement in high risk myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 551-552.	0.6	4
378	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1-9.	1.0	4

#	ARTICLE	IF	CITATIONS
379	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq1 1 0.784314 rgBT /Overlo 2018, 59, 983-987.	0.6	4
380	Nonlethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. Journal of Cellular and Molecular Medicine, 2019, 23, 8010-8018.	1.6	4
381	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities.. Blood, 2009, 114, 958-958.	0.6	4
382	Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma. Blood, 2010, 116, 2967-2967.	0.6	4
383	Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma. Blood, 2010, 116, 2969-2969.	0.6	4
384	Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. Blood, 2011, 118, 5083-5083.	0.6	4
385	Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment. Blood, 2013, 122, 3090-3090.	0.6	4
386	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. Blood, 2014, 124, 306-306.	0.6	4
387	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	0.6	4
388	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 2736-2736.	0.6	4
389	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. Blood, 2020, 136, 21-21.	0.6	4
390	High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	2.5	4
391	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. Journal of Clinical Medicine, 2022, 11, 3355.	1.0	4
392	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1776-1780.	0.6	3
393	Daratumumab combinations: what can we learn?. Blood, 2017, 130, 957-958.	0.6	3
394	Denosumab for myeloma bone disease: ready for prime time?. Lancet Oncology, The, 2018, 19, 277-278.	5.1	3
395	Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 52-53.	1.4	3
396	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. Leukemia and Lymphoma, 2020, 61, 3247-3250.	0.6	3

#	ARTICLE	IF	CITATIONS
397	Emerging drugs for the treatment of Waldenström macroglobulinemia. Expert Opinion on Emerging Drugs, 2020, 25, 433-444.	1.0	3
398	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers, 2021, 13, 763.	1.7	3
399	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. Blood, 2018, 132, 1966-1966.	0.6	3
400	Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures.. Blood, 2007, 110, 3609-3609.	0.6	3
401	Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.. Blood, 2008, 112, 1725-1725.	0.6	3
402	A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.. Blood, 2009, 114, 428-428.	0.6	3
403	The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD) Tj ETQq1 1 0.784314 rgBT /Over Prospective Multicenter Study. Blood, 2010, 116, 3052-3052.	0.6	3
404	Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury.. Blood, 2012, 120, 2919-2919.	0.6	3
405	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. Blood, 2014, 124, 2113-2113.	0.6	3
406	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. Blood, 2014, 124, 4738-4738.	0.6	3
407	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenström's Macroglobulinemia. Blood, 2015, 126, 2096-2096.	0.6	3
408	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. Blood, 2015, 126, 4201-4201.	0.6	3
409	Thrombotic Microangiopathy in Multiple Myeloma. Blood, 2015, 126, 5317-5317.	0.6	3
410	Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. Blood, 2010, 116, 1941-1941.	0.6	3
411	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. Blood, 2020, 136, 11-11.	0.6	3
412	Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. American Journal of Hematology, 2022, 97, 719-730.	2.0	3
413	High dose therapy for light chain amyloidosis: Can we reduce treatment related mortality further?. Leukemia and Lymphoma, 2008, 49, 4-5.	0.6	2
414	VWF, WM, and angiogenesis: is there a link?. Blood, 2012, 120, 3163-3164.	0.6	2



#	ARTICLE	IF	CITATIONS
415	Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 312-323.	0.6	2
416	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, 121-133.		2
417	Carfilzomib for treating myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 989-999.	0.5	2
418	Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1537-1542.	1.3	2
419	Managing myeloma with limited resources in the era of novel drugs. <i>Leukemia and Lymphoma</i> , 2018, 59, 2269-2270.	0.6	2
420	Incidence of Skeletal-Related Events at Diagnosis and at the Time of First Relapse in 463 Patients with Multiple Myeloma Who Received First Line Treatment in a Single Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S333.	0.2	2
421	&lt;p&gt;Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a caseâ€“control study&lt;/p&gt;. <i>Oncotargets and Therapy</i> , 2019, Volume 12, 4195-4202.	1.0	2
422	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28.	0.2	2
423	Screening for Gaucher disease among patients with plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 2021, 62, 761-763.	0.6	2
424	The Utility of Non-LGE Cardiac Magnetic Resonance Imaging Parameters in the Diagnosis of Cardiac Amyloidosis. <i>Heart Lung and Circulation</i> , 2021, 30, e137-e138.	0.2	2
425	Utilization and tolerance of beta-blockers among patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 31-37.	1.4	2
426	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. <i>Blood</i> , 2007, 110, 2739-2739.	0.6	2
427	The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.. <i>Blood</i> , 2007, 110, 3596-3596.	0.6	2
428	Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.. <i>Blood</i> , 2009, 114, 3863-3863.	0.6	2
429	Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.. <i>Blood</i> , 2009, 114, 954-954.	0.6	2
430	Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma. <i>Blood</i> , 2012, 120, 4028-4028.	0.6	2
431	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenströmâ€™s Macroglobulinemia. <i>Blood</i> , 2013, 122, 1860-1860.	0.6	2
432	The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors. <i>Blood</i> , 2013, 122, 1930-1930.	0.6	2

#	ARTICLE	IF	CITATIONS
433	Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 4491-4491.	0.6	2
434	Competing Risk Survival Analysis In Patients With Symptomatic Waldenström's Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years. <i>Blood</i> , 2013, 122, 3197-3197.	0.6	2
435	OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S22.	0.2	2
436	Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy. <i>Blood</i> , 2021, 138, 2708-2708.	0.6	2
437	Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality. <i>Blood</i> , 2021, 138, 1636-1636.	0.6	2
438	Future Developments in the Treatment of AL Amyloidosis. <i>Hemato</i> , 2022, 3, 131-152.	0.2	2
439	Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2007, 28, 109-16.	0.3	2
440	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.	1.0	2
441	Systemic Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1912-1915.	2.2	1
442	Prognostication of the High-Risk WM Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 127-129.	0.2	1
443	Reply to S. Girnius et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2750-2751.	0.8	1
444	Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2016, 2, 1261.	3.4	1
445	Prognosis and risk assessment in AL amyloidosis - There and back again. <i>British Journal of Haematology</i> , 2017, 177, 343-345.	1.2	1
446	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e40-e41.	0.2	1
447	Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S285-S286.	0.2	1
448	Thalidomide for myeloma: still here?. <i>Lancet Haematology</i> , 2018, 5, e439-e440.	2.2	1
449	A 50-Year-Long Study of Waldenström Macroglobulinemia. <i>Mayo Clinic Proceedings</i> , 2019, 94, 394-396.	1.4	1
450	Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e320-e321.	0.2	1

#	ARTICLE	IF	CITATIONS
451	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e5-e6.	0.2	1
452	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.	1.0	1
453	Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1947-1952.	0.5	1
454	Cardiac amyloidosis presenting with coronary artery embolization. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 883.	0.5	1
455	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Blood</i> , 2018, 132, 3295-3295.	0.6	1
456	Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma Treated with High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents.. <i>Blood</i> , 2006, 108, 3586-3586.	0.6	1
457	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. <i>Blood</i> , 2007, 110, 191-191.	0.6	1
458	Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).. <i>Blood</i> , 2008, 112, 1734-1734.	0.6	1
459	Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.. <i>Blood</i> , 2009, 114, 955-955.	0.6	1
460	Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens. <i>Blood</i> , 2010, 116, 3033-3033.	0.6	1
461	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. <i>Blood</i> , 2011, 118, 806-806.	0.6	1
462	High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease. <i>Blood</i> , 2012, 120, 3967-3967.	0.6	1
463	Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse. <i>Blood</i> , 2013, 122, 1916-1916.	0.6	1
464	Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP. <i>Blood</i> , 2013, 122, 3112-3112.	0.6	1
465	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). <i>Blood</i> , 2013, 122, 3196-3196.	0.6	1
466	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.	0.6	1
467	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. <i>Blood</i> , 2016, 128, 2957-2957.	0.6	1
468	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. <i>Blood</i> , 2016, 128, 3310-3310.	0.6	1

#	ARTICLE	IF	CITATIONS
469	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 648-648.	0.6	1
470	Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens. <i>Blood</i> , 2007, 110, 4745-4745.	0.6	1
471	The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients. <i>Blood</i> , 2011, 118, 3961-3961.	0.6	1
472	High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2011, 118, 2893-2893.	0.6	1
473	Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients ≥65 Years of Age Compared to Patients <65 Years. <i>Blood</i> , 2012, 120, 4030-4030.	0.6	1
474	The Role of Angiopoietins System in Waldenström's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival. <i>Blood</i> , 2012, 120, 3901-3901.	0.6	1
475	Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies. <i>Blood</i> , 2012, 120, 1786-1786.	0.6	1
476	High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens. <i>Blood</i> , 2012, 120, 935-935.	0.6	1
477	Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction. <i>Blood</i> , 2013, 122, 3176-3176.	0.6	1
478	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. <i>Blood</i> , 2013, 122, 1867-1867.	0.6	1
479	Lenalidomide Administration In Patients With POEMS Syndrome. <i>Blood</i> , 2013, 122, 3235-3235.	0.6	1
480	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3461-3461.	0.6	1
481	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Blood</i> , 2015, 126, 4188-4188.	0.6	1
482	Successful treatment with lenalidomide dexamethasone for second relapse of a patient with non-secretory multiple myeloma with extramedullary liver plasmacytomas: A case report. <i>Hematology &amp; Medical Oncology</i> , 2017, 2, .	0.1	1
483	Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. <i>Oncotarget</i> , 2018, 9, 12536-12537.	0.8	1
484	Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenström's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. <i>Blood</i> , 2018, 132, 1978-1978.	0.6	1
485	Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 150-150.	0.6	1
486	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. <i>Blood</i> , 2018, 132, 1968-1968.	0.6	1

#	ARTICLE	IF	CITATIONS
487	Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. <i>Blood</i> , 2021, 138, 1668-1668.	0.6	1
488	High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 2526-2526.	0.6	1
489	Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study. <i>Blood</i> , 2021, 138, 2737-2737.	0.6	1
490	Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. <i>Blood</i> , 2021, 138, 2729-2729.	0.6	1
491	Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase $\alpha$ . <i>Blood</i> , 2020, 136, 34-35.	0.6	1
492	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 25-25.	0.6	1
493	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020, 136, 33-33.	0.6	1
494	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. <i>Blood</i> , 2020, 136, 28-28.	0.6	1
495	Monoclonal antibody-based therapies for Waldenström's macroglobulinemia. <i>Leukemia Research Reports</i> , 2022, 17, 100324.	0.2	1
496	Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study. <i>International Journal of Cardiology</i> , 2022, 363, 102-110.	0.8	1
497	DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA. , 0, , 150-163.		0
498	Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S30-S32.	1.4	0
499	High dose melphalan in primary systemic amyloidosis: status quo?. <i>Leukemia and Lymphoma</i> , 2010, 51, 2149-2151.	0.6	0
500	Waldenström's Macroglobulinemia. , 2013, , 681-699.		0
501	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S75.	0.2	0
502	Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S76-S77.	0.2	0
503	A Revised Staging System for Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S332-S333.	0.2	0
504	Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S332.	0.2	0

#	ARTICLE	IF	CITATIONS
505	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients With AL amyloidosis Treated With Bortezomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e65-e66.	0.2	0
506	Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e143-e144.	0.2	0
507	RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e143.	0.2	0
508	Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e40.	0.2	0
509	Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e62-e63.	0.2	0
510	Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e115-e116.	0.2	0
511	Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. , 2017, , 239-261.		0
512	Immunomodulatory Agents and Proteasome Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 335-343.		0
513	Primary Systemic Amyloidosis. <i>Hematologic Malignancies</i> , 2018, , 221-245.	0.2	0
514	The role of ibrutinib in Waldenström macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 85-89.	0.5	0
515	Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström's Macroglobulinemia (iNNOVATE). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S283.	0.2	0
516	Clinical Characteristics and Outcomes of Oligosecretory and Non-Secretory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S237-S238.	0.2	0
517	Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, xiii-xiv.	0.9	0
518	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy Naïve Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAT-CAT-MM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S235-S236.	0.2	0
519	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S250-S251.	0.2	0
520	Monoclonal Antibodies for Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 841-852.	0.9	0
521	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S325.	0.2	0
522	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S331-S332.	0.2	0

#	ARTICLE	IF	CITATIONS
523	Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e38-e39.	0.2	0
524	Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e185-e186.	0.2	0
525	Clonal Heterogeneity and Immune Tumor Microenvironment in Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e318-e319.	0.2	0
526	Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e58-e59.	0.2	0
527	Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e190-e191.	0.2	0
528	High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e28-e29.	0.2	0
529	Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e121-e122.	0.2	0
530	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 607571.	1.3	0
531	MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S297-S298.	0.2	0
532	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2246-2249.	0.6	0
533	Mutation-dependent treatment approaches for patients with complex multiple myeloma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 189-201.	0.4	0
534	Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14558-e14558.	0.8	0
535	Managing complications secondary to Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 2021, 14, 1-12.	1.0	0
536	Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenström's Macroglobulinemia: Correlations with Clinical Data.. <i>Blood</i> , 2005, 106, 2504-2504.	0.6	0
537	Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.. <i>Blood</i> , 2006, 108, 5000-5000.	0.6	0
538	Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2006, 108, 3095-3095.	0.6	0
539	Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5018-5018.	0.6	0
540	Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenström's Macroglobulinemia (WM): Correlations with Clinical Data.. <i>Blood</i> , 2006, 108, 5006-5006.	0.6	0

#	ARTICLE	IF	CITATIONS
541	Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.. Blood, 2007, 110, 4812-4812.	0.6	0
542	The International Prognostic Scoring System for Waldenström's Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.. Blood, 2007, 110, 3615-3615.	0.6	0
543	High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.. Blood, 2007, 110, 4781-4781.	0.6	0
544	Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.. Blood, 2007, 110, 4729-4729.	0.6	0
545	The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.. Blood, 2007, 110, 1478-1478.	0.6	0
546	Symptomatic Waldenström's Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. Blood, 2007, 110, 4730-4730.	0.6	0
547	Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients. Blood, 2008, 112, 5143-5143.	0.6	0
548	Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis. Blood, 2008, 112, 2731-2731.	0.6	0
549	Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenström's Macroglobulinemia: Implications into the Biology of the Disease. Blood, 2008, 112, 5108-5108.	0.6	0
550	Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG). Blood, 2008, 112, 655-655.	0.6	0
551	Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trepine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2008, 112, 5119-5119.	0.6	0
552	The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis.. Blood, 2008, 112, 1728-1728.	0.6	0
553	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met.. Blood, 2008, 112, 1726-1726.	0.6	0
554	Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.. Blood, 2009, 114, 1824-1824.	0.6	0
555	Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3334-3334.	0.6	0
556	Validation of the International Prognostic Scoring System (IPSS) for Waldenström's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).. Blood, 2009, 114, 2845-2845.	0.6	0
557	The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.. Blood, 2009, 114, 2279-2279.	0.6	0
558	Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.. Blood, 2009, 114, 3871-3871.	0.6	0



#	ARTICLE	IF	CITATIONS
559	Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.. Blood, 2009, 114, 829-829.	0.6	0
560	Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.. Blood, 2009, 114, 1741-1741.	0.6	0
561	The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.. Blood, 2009, 114, 730-730.	0.6	0
562	Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti-MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo. , 2009, , .		0
563	Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis. Blood, 2010, 116, 3048-3048.	0.6	0
564	Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.. Blood, 2010, 116, 1581-1581.	0.6	0
565	Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years. Blood, 2010, 116, 1947-1947.	0.6	0
566	Increased Expression of Cyclin-D1 on Trepine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents. Blood, 2010, 116, 2965-2965.	0.6	0
567	Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma. Blood, 2010, 116, 2976-2976.	0.6	0
568	Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy. Blood, 2010, 116, 3035-3035.	0.6	0
569	Waldenström's Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects. , 2012, , 277-283.		0
570	Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group. Blood, 2011, 118, 5085-5085.	0.6	0
571	Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?. Blood, 2011, 118, 5091-5091.	0.6	0
572	Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival. Blood, 2011, 118, 2894-2894.	0.6	0
573	Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,. Blood, 2011, 118, 3926-3926.	0.6	0
574	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	0.6	0
575	Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology. Blood, 2011, 118, 5059-5059.	0.6	0
576	Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,. Blood, 2011, 118, 3920-3920.	0.6	0

#	ARTICLE	IF	CITATIONS
577	Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis. <i>Blood</i> , 2011, 118, 4457-4457.	0.6	0
578	Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations. <i>Blood</i> , 2011, 118, 2872-2872.	0.6	0
579	Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome. <i>Blood</i> , 2011, 118, 1802-1802.	0.6	0
580	Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy. <i>Blood</i> , 2011, 118, 5067-5067.	0.6	0
581	Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 5081-5081.	0.6	0
582	High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens. <i>Blood</i> , 2011, 118, 5082-5082.	0.6	0
583	Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients. <i>Blood</i> , 2011, 118, 1811-1811.	0.6	0
584	Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System. <i>Blood</i> , 2011, 118, 4396-4396.	0.6	0
585	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma,. <i>Blood</i> , 2011, 118, 3918-3918.	0.6	0
586	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. <i>Blood</i> , 2012, 120, 948-948.	0.6	0
587	The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation. <i>Blood</i> , 2012, 120, 1849-1849.	0.6	0
588	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. <i>Blood</i> , 2013, 122, 1866-1866.	0.6	0
589	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 1861-1861.	0.6	0
590	Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens. <i>Blood</i> , 2013, 122, 3091-3091.	0.6	0
591	Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients. <i>Blood</i> , 2013, 122, 3130-3130.	0.6	0
592	Multiple Myeloma Patients >40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3226-3226.	0.6	0
593	Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers. <i>Blood</i> , 2013, 122, 3194-3194.	0.6	0
594	Circulating Levels of Angiogenic Cytokines in Waldenström's Macroglobulinemia: Clinical Correlations. <i>Current Angiogenesis</i> , 2014, 2, 104-109.	0.1	0

#	ARTICLE	IF	CITATIONS
595	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. Blood, 2014, 124, 3488-3488.	0.6	0
596	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. Blood, 2014, 124, 2132-2132.	0.6	0
597	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. Blood, 2014, 124, 2028-2028.	0.6	0
598	No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience. Blood, 2014, 124, 4752-4752.	0.6	0
599	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 2029-2029.	0.6	0
600	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2014, 124, 3462-3462.	0.6	0
601	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. Blood, 2014, 124, 3464-3464.	0.6	0
602	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. Blood, 2014, 124, 2130-2130.	0.6	0
603	Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications. Blood, 2014, 124, 276-276.	0.6	0
604	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	0.6	0
605	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.	0.6	0
606	Translating Findings of Proteasome Inhibitors Effects from the in Vivo Drosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.	0.6	0
607	Circulating Adams-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. Blood, 2014, 124, 5741-5741.	0.6	0
608	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	0.6	0
609	Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia. , 2015, , .		0
610	The patient with myeloma. , 2015, , 1276-1291.		0
611	Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. Blood, 2015, 126, 1832-1832.	0.6	0
612	Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. Blood, 2015, 126, 3250-3250.	0.6	0

#	ARTICLE	IF	CITATIONS
613	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.	0.6	0
614	Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. <i>Blood</i> , 2015, 126, 3054-3054.	0.6	0
615	Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. <i>Blood</i> , 2015, 126, 4251-4251.	0.6	0
616	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. <i>Blood</i> , 2015, 126, 1074-1074.	0.6	0
617	Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. <i>Blood</i> , 2015, 126, 4242-4242.	0.6	0
618	Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens. <i>Blood</i> , 2016, 128, 4446-4446.	0.6	0
619	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. <i>Blood</i> , 2016, 128, 4488-4488.	0.6	0
620	Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death. <i>Blood</i> , 2016, 128, 2954-2954.	0.6	0
621	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	0.6	0
622	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 3259-3259.	0.6	0
623	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 4490-4490.	0.6	0
624	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016, 128, 4500-4500.	0.6	0
625	Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival. <i>Blood</i> , 2016, 128, 4492-4492.	0.6	0
626	Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 8003-8003.	0.8	0
627	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.	0.6	0
628	Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo. <i>Blood</i> , 2018, 132, 3214-3214.	0.6	0
629	Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd. <i>Blood</i> , 2018, 132, 3246-3246.	0.6	0
630	OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S23-S24.	0.2	0

#	ARTICLE	IF	CITATIONS
631	P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S104.	0.2	0
632	P-009: Assessing the predictive utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: a systematic literature review and meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S43-S44.	0.2	0
633	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.	0.6	0
634	Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine. <i>Blood</i> , 2021, 138, 3802-3802.	0.6	0
635	Single Cell Analysis of MYD88 L265P and MYD88 WT Waldenström Macroglobulinemia Patients. <i>Blood</i> , 2021, 138, 1599-1599.	0.6	0
636	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. <i>Blood</i> , 2021, 138, 723-723.	0.6	0
637	The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. <i>Blood</i> , 2021, 138, 2394-2394.	0.6	0
638	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. <i>Blood</i> , 2021, 138, 4771-4771.	0.6	0
639	Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy. <i>Blood</i> , 2021, 138, 3799-3799.	0.6	0
640	Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenström's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination. <i>Blood</i> , 2021, 138, 3791-3791.	0.6	0
641	De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment. <i>HemaSphere</i> , 2021, 5, e665.	1.2	0
642	Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study. <i>Blood</i> , 2021, 138, 1672-1672.	0.6	0
643	Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. <i>Blood</i> , 2021, 138, 3752-3752.	0.6	0
644	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.	0.6	0
645	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020, 136, 8-8.	0.6	0
646	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. <i>Blood</i> , 2020, 136, 19-20.	0.6	0
647	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	0.6	0
648	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. <i>Blood</i> , 2020, 136, 33-34.	0.6	0

#	ARTICLE	IF	CITATIONS
649	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
650	Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. <i>Blood</i> , 2020, 136, 18-18.	0.6	0
651	Author's reply: To PMID 23705905. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 300.	0.9	0
652	Daratumumab for Immunoglobulin Light Chain Amyloidosis. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 79.	0.1	0